甘李药业股份有限公司关于持股5%以上股东权益变动达1%的提示性公告

Core Viewpoint - The equity change by a major shareholder of Ganli Pharmaceutical Co., Ltd. does not lead to a change in the controlling shareholder or actual controller of the company [2][6]. Group 1: Equity Change Details - After the equity change, Beijing Xutong Hongda Technology Co., Ltd. holds 40,634,035 shares, accounting for 6.76% of the total share capital [2]. - The associated party, Mr. Gan Zhongru, holds 205,643,757 shares, representing 34.21% of the total share capital, bringing the total combined holdings to 246,277,792 shares, or 40.97% of the total [2][3]. - Prior to the change, Xutong Hongda held 41,483,857 shares, which was 6.90% of the total share capital, and the combined holdings were 247,127,614 shares, or 41.11% [3]. Group 2: Compliance and Impact - The equity change complies with relevant laws and regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [3][5]. - The equity change is a normal reduction by the shareholder and will not significantly impact the company's governance structure or ongoing operations [6]. - The shares involved in this equity change all enjoy voting rights without any restrictions on transfer or delegation [4][6].